A Phase 1b/2 Open-Label Study of Disitamab Vedotin in Combination With Other Anticancer Therapies in Solid Tumors
This study is testing a new way to treat advanced breast and stomach cancers that have a specific protein called HER2. Researchers want to see if combining two targeted therapies can help stop or slow down cancer that has become harder to treat with standard options.
This study is for adults with advanced or spreading breast or stomach cancer that has progressed despite previous treatments. Participants must have a confirmed HER2-positive diagnosis and be well enough to carry out normal daily activities.
Participants will receive a combination of two targeted drugs: disitamab vedotin, which delivers chemotherapy directly to cancer cells, and tucatinib, which helps block cancer growth. Doctors will carefully monitor participants to see how well the treatment works and to identify any side effects that might occur.
The study is currently active but not recruiting new participants, and it is located in Tucson, Arizona. Please consult your oncology team or a clinical trial specialist to see if similar future studies might be an option for you.
- 1The treatment uses a 'targeted' approach to aim specifically at cancer cells while sparing healthy ones.
- 2This trial is for patients whose cancer has not responded to or was too difficult to manage with standard therapies.
- 3Safety is a top priority, and doctors will be watching closely for any side effects throughout the study.
No related links yet
Seen this study covered in the news, or found a page that explains it well? Send it over and we'll review it.
Suggest a linkThis summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.